Rho kinase inhibitors for primary open-angle glaucoma and ocular hypertension

<p>Glaucoma is a common eye condition and a major cause of blindness. There are several Cochrane reviews of ways to treat it and these were added to in June 2022 with a new review of a class of drugs called rho kinase inhibitors. We asked lead author, Josefine Freiberg from the University of Copenhagen in Denmark to tell us about the evidence in this podcast.</p>